Briefing
Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study.
A single-institution prospective study tested the feasibility of serial Signatera ctDNA monitoring in clinical stage IIB, IIC, and III melanoma.
- Design: Evidence level 3
- Assay: Signatera
Annals of Surgical OncologyPubMed 40146490DOI 10.1245/s10434-025-17194-z